Recent Updates in the Role of Wearable Cardioverter Defibrillator for Prevention of Sudden Cardiac Death

Irene Kirolos, David Jones, Kirstin Hesterberg, Charles Yarn, Rami Khouzam, Yehoshua C. Levine

Research output: Contribution to journalReview article

Abstract

Purpose of review: The wearable cardioverter defibrillator (WCD) or LifeVest may protect against sudden cardiac death (SCD) in patients awaiting insertion of an implantable cardioverter defibrillator (ICD). The purpose of this communication is to review the rationale behind WCD therapy and to critically analyze recent data regarding its clinical efficacy. We seek to provide evidence-based recommendations regarding the potential role of the WCD in certain populations. Recent findings: The only randomized controlled trial that evaluated WCD therapy did not demonstrate a reduced rate of arrhythmic death in patients prescribed the WCD during the first 90-day post-myocardial infarction (MI). However, when considering trial results alongside previous retrospective data, patient noncompliance with WCD therapy—rather than ineffectiveness of WCD therapy—remains an important theme. Summary: The uncertainty of data regarding the use of WCD therapy in patients during ICD waiting periods should be considered as part of the shared decision processes between healthcare providers and patients. Higher rates of adherence are needed to ensure efficiency. Well-designed future studies with appropriate cost-effectiveness analyses are indicated to define the clinical efficacy of WCD therapy on arrhythmic and non-arrhythmic morbidity and mortality in patients who are not yet candidates for ICDs.

Original languageEnglish (US)
Article number49
JournalCurrent Treatment Options in Cardiovascular Medicine
Volume21
Issue number9
DOIs
StatePublished - Sep 1 2019

Fingerprint

Defibrillators
Sudden Cardiac Death
Implantable Defibrillators
Therapeutics
Mortality
Patient Compliance
Health Personnel
Uncertainty
Cost-Benefit Analysis
Randomized Controlled Trials
Myocardial Infarction
Morbidity

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Recent Updates in the Role of Wearable Cardioverter Defibrillator for Prevention of Sudden Cardiac Death. / Kirolos, Irene; Jones, David; Hesterberg, Kirstin; Yarn, Charles; Khouzam, Rami; Levine, Yehoshua C.

In: Current Treatment Options in Cardiovascular Medicine, Vol. 21, No. 9, 49, 01.09.2019.

Research output: Contribution to journalReview article

Kirolos, Irene ; Jones, David ; Hesterberg, Kirstin ; Yarn, Charles ; Khouzam, Rami ; Levine, Yehoshua C. / Recent Updates in the Role of Wearable Cardioverter Defibrillator for Prevention of Sudden Cardiac Death. In: Current Treatment Options in Cardiovascular Medicine. 2019 ; Vol. 21, No. 9.
@article{84afa6e865394f8a9e4b617cfc070acf,
title = "Recent Updates in the Role of Wearable Cardioverter Defibrillator for Prevention of Sudden Cardiac Death",
abstract = "Purpose of review: The wearable cardioverter defibrillator (WCD) or LifeVest may protect against sudden cardiac death (SCD) in patients awaiting insertion of an implantable cardioverter defibrillator (ICD). The purpose of this communication is to review the rationale behind WCD therapy and to critically analyze recent data regarding its clinical efficacy. We seek to provide evidence-based recommendations regarding the potential role of the WCD in certain populations. Recent findings: The only randomized controlled trial that evaluated WCD therapy did not demonstrate a reduced rate of arrhythmic death in patients prescribed the WCD during the first 90-day post-myocardial infarction (MI). However, when considering trial results alongside previous retrospective data, patient noncompliance with WCD therapy—rather than ineffectiveness of WCD therapy—remains an important theme. Summary: The uncertainty of data regarding the use of WCD therapy in patients during ICD waiting periods should be considered as part of the shared decision processes between healthcare providers and patients. Higher rates of adherence are needed to ensure efficiency. Well-designed future studies with appropriate cost-effectiveness analyses are indicated to define the clinical efficacy of WCD therapy on arrhythmic and non-arrhythmic morbidity and mortality in patients who are not yet candidates for ICDs.",
author = "Irene Kirolos and David Jones and Kirstin Hesterberg and Charles Yarn and Rami Khouzam and Levine, {Yehoshua C.}",
year = "2019",
month = "9",
day = "1",
doi = "10.1007/s11936-019-0746-z",
language = "English (US)",
volume = "21",
journal = "Current Treatment Options in Cardiovascular Medicine",
issn = "1092-8464",
publisher = "Current Science, Inc.",
number = "9",

}

TY - JOUR

T1 - Recent Updates in the Role of Wearable Cardioverter Defibrillator for Prevention of Sudden Cardiac Death

AU - Kirolos, Irene

AU - Jones, David

AU - Hesterberg, Kirstin

AU - Yarn, Charles

AU - Khouzam, Rami

AU - Levine, Yehoshua C.

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Purpose of review: The wearable cardioverter defibrillator (WCD) or LifeVest may protect against sudden cardiac death (SCD) in patients awaiting insertion of an implantable cardioverter defibrillator (ICD). The purpose of this communication is to review the rationale behind WCD therapy and to critically analyze recent data regarding its clinical efficacy. We seek to provide evidence-based recommendations regarding the potential role of the WCD in certain populations. Recent findings: The only randomized controlled trial that evaluated WCD therapy did not demonstrate a reduced rate of arrhythmic death in patients prescribed the WCD during the first 90-day post-myocardial infarction (MI). However, when considering trial results alongside previous retrospective data, patient noncompliance with WCD therapy—rather than ineffectiveness of WCD therapy—remains an important theme. Summary: The uncertainty of data regarding the use of WCD therapy in patients during ICD waiting periods should be considered as part of the shared decision processes between healthcare providers and patients. Higher rates of adherence are needed to ensure efficiency. Well-designed future studies with appropriate cost-effectiveness analyses are indicated to define the clinical efficacy of WCD therapy on arrhythmic and non-arrhythmic morbidity and mortality in patients who are not yet candidates for ICDs.

AB - Purpose of review: The wearable cardioverter defibrillator (WCD) or LifeVest may protect against sudden cardiac death (SCD) in patients awaiting insertion of an implantable cardioverter defibrillator (ICD). The purpose of this communication is to review the rationale behind WCD therapy and to critically analyze recent data regarding its clinical efficacy. We seek to provide evidence-based recommendations regarding the potential role of the WCD in certain populations. Recent findings: The only randomized controlled trial that evaluated WCD therapy did not demonstrate a reduced rate of arrhythmic death in patients prescribed the WCD during the first 90-day post-myocardial infarction (MI). However, when considering trial results alongside previous retrospective data, patient noncompliance with WCD therapy—rather than ineffectiveness of WCD therapy—remains an important theme. Summary: The uncertainty of data regarding the use of WCD therapy in patients during ICD waiting periods should be considered as part of the shared decision processes between healthcare providers and patients. Higher rates of adherence are needed to ensure efficiency. Well-designed future studies with appropriate cost-effectiveness analyses are indicated to define the clinical efficacy of WCD therapy on arrhythmic and non-arrhythmic morbidity and mortality in patients who are not yet candidates for ICDs.

UR - http://www.scopus.com/inward/record.url?scp=85070353026&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070353026&partnerID=8YFLogxK

U2 - 10.1007/s11936-019-0746-z

DO - 10.1007/s11936-019-0746-z

M3 - Review article

VL - 21

JO - Current Treatment Options in Cardiovascular Medicine

JF - Current Treatment Options in Cardiovascular Medicine

SN - 1092-8464

IS - 9

M1 - 49

ER -